Solving the hardest problems in cell therapy.
Developing effective cell therapies for solid tumors is one of the most challenging endeavors in modern medicine. While these treatments achieve remarkable success in blood cancers, the majority fail when applied to solid tumors.
The challenge isn't the therapy itself—it's access. Most immune cells simply can't reach solid tumor sites, creating a fundamental bottleneck that limits therapeutic success.
We're changing that. Through predictive cell characterization, we identify which immune cells have the best chance of infiltrating tumors—at the most critical decision points from early development through clinical trials.
Our mission.
To revolutionize cancer treatment by identifying the most effective immune cells for each patient, accelerating the development of life-saving cell therapies for solid tumors.
Our news.
Stay updated on our latest achievements, publications, and milestones as we advance cell therapy development for solid tumors.
Showing 9 of 9 news items
Infiltrate Bio Joins Roseman Bioventures to Optimize Tumor-Infiltrating Cell Therapies
Infiltrate Bio joins Roseman Bioventures, one of the largest dedicated life science incubators in the Intermountain West with supporting sponsors that include J.P. Morgan. The residency will accelerate the company's biomimetic platform for predicting and enriching tumor-infiltrating immune cells in solid tumors.
Infiltrate Bio Selected for Palantir Startup Fellowship
Infiltrate Bio joins the Palantir Startup Fellowship Cohort #002. Palantir Foundry will enable scalable data infrastructure and predictive machine learning to advance next generation immune therapies for the world's most complex diseases.
Infiltrate Bio Selected as AWS AI Competition Winner
Infiltrate Bio was selected as a winner at the AWS AI Competition in Nevada, sponsored by Amazon Web Services (AWS), Eficens Systems, and RSNA Cloud Connect. The POC funding will advance the company's predictive platform for cell and immune therapies—helping researchers identify, predict, and optimize therapeutic cells with superior tumor infiltration characteristics.
Infiltrate Bio Awarded Biolocity Funding to Accelerate Immune Cell Therapy Innovation
Received Biolocity funding to accelerate the development of our adhesion chromatography platform for immune cell therapy optimization and clinical translation.
Infiltrate Bio's Foundational Technology Advances Field of T Cell Selection and Manufacturing
Nature Reviews Bioengineering publication covers breakthrough approaches for identifying, engineering, screening and sorting therapeutic T cells
Infiltrate Bio Secures Georgia Research Alliance Phase 1 Funding for Early-Stage Development
Secured Georgia Research Alliance Phase 1 funding to support early-stage platform development and validation studies for predictive cell characterization technology.
Infiltrate Bio's Technology Platform Enables Precision Selection of Superior Immune Cells for Cancer Therapy
Cell Reports Methods publication validates company's foundational technology for real-time, single-cell profiling that identifies therapeutic T lymphocytes with enhanced tumor infiltrating potential
Infiltrate Bio Technology Platform Featured in The Scientist for Breakthrough T Cell Homing Technology
The Scientist highlights company's foundational technology platform that identifies engineered immune cells with superior tumor-targeting potential to advance solid tumor therapies
Infiltrate Bio's Core Technology Approach Demonstrates up to 4x Improvement in Tumor Infiltrating T Cells
Breakthrough research published in Cell Reports validates the tumor vasculature-mimicking technology that powers company's platform, achieving 3-4x enhanced tumor infiltration in preclinical models